FDA again raises doubts on Stealth's ultra-rare disease drug ahead of adcomm
Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval or even an accelerated approval, agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
